Endocrine tumors associated with the vagus nerve

Arthur Varoquaux1, Electron Kebebew2, Frédéric Sebag3, Katherine Wolf4, Jean-François Henry3, Karel Pacak4 and David Taïeb5

1Department of Radiology, Conception Hospital, Aix-Marseille University, Marseille, France
2Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
3Department of Endocrine Surgery, Conception Hospital, Aix-Marseille University, Marseille, France
4Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland, USA
5Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France

Abstract

The vagus nerve (cranial nerve X) is the main nerve of the parasympathetic division of the autonomic nervous system. Vagal paragangliomas (VPGLs) are a prime example of an endocrine tumor associated with the vagus nerve. This rare, neural crest tumor constitutes the second most common site of hereditary head and neck paragangliomas (HNPGGLs), most often in relation to mutations in the succinate dehydrogenase complex subunit D (SDHD) gene. The treatment paradigm for VPGL has progressively shifted from surgery to abstinence or therapeutic radiation with curative-like outcomes. Parathyroid tissue and parathyroid adenoma can also be found in close association with the vagus nerve in intra or paravagal situations. Vagal parathyroid adenoma can be identified with preoperative imaging or suspected intraoperatively by experienced surgeons. Vagal parathyroid adenomas located in the neck or superior mediastinum can be removed via initial cervicotomy, while those located in the aortopulmonary window require a thoracic approach. This review particularly emphasizes the embryology, molecular genetics, and modern imaging of these tumors.

Vagus nerve

The vagus nerve (cranial nerve X) is the main nerve of the parasympathetic division of the autonomic nervous system. It originates from the medulla oblongata and exits the skull base via the jugular foramen (pars vascularis). The vagus nerve descends vertically through the neck within the carotid sheath (Fig. 1) and into the mediastinum with different paths on the left and right sides. Among the different branches that innervate the laryngeal and pharyngeal muscles, the recurrent laryngeal nerves (RLNs) are of major clinical importance.

The vagus nerve contains sensory (80–90%) and motor fibers and serves as the communication pathway between the CNS (hypothalamus and its connections) and the viscera. The parasympathetic system regulates ‘rest and digestive’ functions. Afferent signaling via the vagus nerve transmits visceral stimuli (taste buds, heart, lungs, and other visceral organs) to the nucleus of the solitary tract. The cell bodies of these fibers are located in the inferior ganglion (nodose ganglion) of the vagus nerve. Somatic sensory fibers arising from the external ear have their cell bodies in the superior (jugular) ganglion.

Key Words
- vagus nerve
- paragangliomas
- hyperparathyroidism
- diagnostic imaging
and then project to the trigeminal nucleus (Baker 2005). Vagus motor fibers arising from the dorsal motor nucleus innervate visceral organs (heart, digestive system), and those from the nucleus ambiguus are involved in speech and swallowing.

From an embryology standpoint, preganglionic motor and somatic sensory neurons, as well as supporting cells of the cranial ganglia, arise from neural crest cells. By contrast, the visceral sensory innervation from the vagus nerve arises from the third epibranchial placode (nodose placode) (Baker 2005).

Vagal paragangliomas

Tumor origin and molecular genetics

Vagus nerve paraganglia belong to the family of parasympathetic paraganglia. Members act as chemoreceptors and are involved in the visceral reflex circuits. Vagus paraganglia derived from the neural crest are constituted by six to seven small collections of paragangionic tissue mainly located at or just below the nodose ganglion (inferior ganglion vagus nerve). It can also be found at the level of the carotid bifurcation or along the vagus nerve in the mediastinum. Vagus paraganglia is morphologically identical to the carotid body with glomus cells (type I) and located within the nerve or adjacent to the nerve (juxta vagus). Although the role of vagus paraganglia is currently largely unknown, it may act as an immunosensory receptor and participate in a neural reflex mechanism during sepsis or injury.

Paragangliomas (PGLs) can arise from all parasympathetic paraganglia sites. They can occur as sporadic or hereditary tumors, with the latter accounting for at least 40% of cases. Of all known genetic mutations, those in the succinate dehydrogenase (SDHx) complex subunit D (SDHD) gene are currently the leading cause of hereditary head and neck PGLs (HNPGLs) (>50%), followed by SDHB (20%) and SDHC mutations (Baysal et al. 2002, Neumann et al. 2009, Piccini et al. 2012). The inheritance pattern of the SDHB and SDHC genes is autosomal dominant, whereas for SDHD, the disease almost always occurs when the mutations are inherited from the father, a mode of inheritance consistent with maternal imprinting (Baysal 2013). Other pheochromocytoma/PPGL predisposing genes are rarely involved in the development of HNPGLs. The vagus PGL (VPGL) arises from paraganglionic tissue associated with the vagus nerve. They represent 13% of sporadic HNPGLs (Erickson et al. 2001) and represent the second most common site (31%) of hereditary HNPGLs after jugular PGL (Gimenez-Roqueplo et al. 2013). VPGLs can be confined to the upper cervical region in the retrostyloid parapharyngeal space, abutting against the jugular foramen and the skull base with either anterior displacement and/or encasement of the internal carotid artery and extend into the jugular foramen, often with intracranial extension.

Genetic and clinical characteristics of nonsyndromic PPGL associated with mutations in the SDHx genes (PGL syndromes 1–5) are detailed in Table 1 (Benn et al. 2015).

Diagnosis and imaging

VPGLs can be associated with subtle signs like pharyngeal discomfort or foreign body sensation, but in many cases, tumors are incidentally discovered and diagnosed in SDHx mutation carriers. Otologic symptoms may also occur in cases of Eustachian tube orifice obstruction. Patients with a suspected VPGL require measurement of plasma metanephrines, methoxytyramine, and plasma chromogranin A, but these markers are often normal. VPGLs are typically found in the parapharyngeal retrostyloid (poststyloid or carotid artery) space. There are many potential differential diagnoses of VPGL: neurogenic tumors (schwannoma, neurofibroma), lymph node metastasis (nasopharynx/oropharynx, thyroid cancer, melanoma); lymphoma; other primary tumors (meningioma, ganglioneuroma, hemangiopericytoma, cavernous hemangioma, sarcoma), and a variety of
uncommon lesions (i.e. abscess, internal carotid artery aneurysm, internal jugular vein thrombosis, vascular malposition or hematoma). Specific data about the relative frequency for various causes of parapharyngeal retrostyloid masses are lacking. Based on our long-standing experience in otolaryngology imaging and case report series, the four main causes of parapharyngeal retrostyloid masses are lymph nodes (approximately 80%), schwannoma (5%), PGL (5%) and neurofibroma (3%) (Pang et al. 2002, Kuet et al. 2015). Other causes account for the remaining 7%. 

The role of imaging is multiple: diagnosis of PGL, staging according to Netterville’s classification, detection of multifocality, and assessment for potential metastases (2). CT and MRI are the cornerstones of initial evaluation. VPGLs, like other HNPGLs, usually demonstrate marked enhancement of intratumoral vessels following contrast administration on CT. On MRI, VPGLs appear as a nonspecific intermediate signal lesion on T1-weighted images, and as a nonspecific intermediate-to-high signal on T2-weighted MRI images. Intense enhancement after gadolinium injection is common. Flow signal voids in the tumor are typical of PGLs, with a ’salt and pepper’ appearance on spin-echo sequences. These flow voids correspond to intratumoral arterial vessels on MR angiography (MRA) (Johnson 1998, Arnold et al. 2003, van den Berg et al. 2004, van den Berg 2005, Neves et al. 2008). These arterial feeders can be imaged with MRA sequences either with (time-resolved gadolinium MRA) or without gadolinium injection on time-of-flight (TOF) sequences (TOF MRA) (Fig. 2). These sequences have been shown to be highly informative, with sensitivities and specificities of 90 and 94% (van den Berg et al. 2004) and 100 and 94% (Neves et al. 2008), respectively. 3D MRA sequences (3D TOF MRA and 3D time-resolved angiography) are more sensitive than conventional 2D sequences, especially in detecting smaller PGLs that can be observed in SDHx mutation carriers (Arnold et al. 2003). Fusion images from 3D co-registered 3D MRA to anatomical data (3D gradient-echo T1-weighted VIBE fat-saturated sequence) are particularly informative. Perfusion MR and diffusion-weighted imaging (DWI), which depend on capillary membrane permeability and tissue cellularity, respectively, are still under evaluation in this indication (Dong & Liu 2012).

A head-to-head comparison between somatostatin analogs (SSA) labeled with gallium-68 (68Ga-DOTASSA) and 18F-fluorodopa (18F-FDOPA) PET has been performed in only five studies: one retrospective study from Innsbruck Medical University (68Ga-DOTATOC in 20 patients with unknown genetic background) (Kroiss et al. 2013), three prospective studies from the National Institutes of Health (SDHB, HNPGL, and sporadic, metastatic) (68Ga-DOTATATE in 17 and 20 patients) (Janssen et al. 2015, 2016a,b), and one prospective study from La Timone University Hospital (68Ga-DOTATATE in 30 patients). In these studies, 68Ga-DOTA-SSA PET/CT detected more primary HNPGLs, as well as SDHx-associated PGLs than 18F-FDOPA PET/CT (Archier et al. 2016) (Fig. 3). This radiopharmaceutical should be considered as the first-line imaging modality for HNPGLs (Table 2). A distinction between VPGL, carotid body PGL (CBP), and exceptional cases of sympathetic PGL could be difficult. At the level of the carotid bifurcation, the distinction between VP and CBP is based on the displacement of the internal and external carotid artery. VP tend to displace both vessels together rather than splaying them as in CBP (’Lyre sign’). This distinction is difficult to ascertain on an unenhanced PET/CT. A thin nipple at the top of the VP, which corresponds to a protrusion of paranganglionic cells within the nerve, can be observed in large tumors.

Proper diagnosis (Fig. 4), staging and early detection of metastatic disease is a key point for choosing the optimal treatment and follow-up plan, as well as insuring the best

<table>
<thead>
<tr>
<th>Gene</th>
<th>Syndrome</th>
<th>Inheritance</th>
<th>HNPGL</th>
<th>Thoracic or retroperitoneal PGL</th>
<th>PHEO</th>
<th>Multifocality</th>
<th>Malignancy risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>SDHA</td>
<td>PGL5</td>
<td>Autosomal dominant</td>
<td>Rare</td>
<td>Rare</td>
<td>Rare</td>
<td>Rare</td>
<td>None reported</td>
</tr>
<tr>
<td>SDHB</td>
<td>PGL4</td>
<td>Autosomal dominant</td>
<td>20–30%</td>
<td>50%</td>
<td>20–25%</td>
<td>30%</td>
<td>30–40%</td>
</tr>
<tr>
<td>SDHC</td>
<td>PGL3</td>
<td>Autosomal dominant</td>
<td>90%</td>
<td>10% (mediastinum)</td>
<td>20–25%</td>
<td>20%</td>
<td>Very rare</td>
</tr>
<tr>
<td>SDHD</td>
<td>PGL1</td>
<td>Autosomal dominant (paternal transmission)</td>
<td>85%</td>
<td>10–25%</td>
<td>50–60%</td>
<td>20%</td>
<td>3–10%</td>
</tr>
<tr>
<td>SDHAF2</td>
<td>PGL2</td>
<td>Autosomal dominant (paternal transmission)</td>
<td>100%</td>
<td>0%</td>
<td>0%</td>
<td>90%</td>
<td>None reported</td>
</tr>
</tbody>
</table>

Adapted from Benn et al. (2015).
patient outcome. CT, whole-body MRI, and PET imaging provide the most useful complementary information. $^{68}$Ga-DOTA-SSA PET/CT seems to have an excellent sensitivity, regardless of genetic background (Janssen et al. 2015, 2016a). If $^{68}$Ga-DOTA-SSA is not available, $^{18}$F-FDOPA PET may be the imaging modality of choice in the absence of a SDHB mutation, or even when the genetic status is unknown (Fig. 5). By contrast, $^{18}$F-FDG PET should be considered as the first alternative imaging for SDHx-related cases.

**Treatment**

Treatment of VPGLs is challenging for a number of reasons. Although these tumors are generally benign, there may be a mass effect or invasion of surrounding critical and delicate structures, invasion of the skull base, and extension intracranially. VPGLs have an intimate relationship to the other cranial nerves at the skull base and thus, may present in some patients as cranial nerve palsy. Additionally, VPGLs have a high propensity to be multicentric and bilateral, especially in hereditary forms (Table 1). The reported malignancy risks of HNPGLs usually ranges from 3 to 7%. VPGLs have a lower malignancy risk compared with their carotid counterparts. Tumors with gross tumor infiltration into surrounding structures and/or related to SDHx (B > D) mutations should be considered at a higher risk for malignancy, although properly designed studies have not been done (Boedeker et al. 2007, van Hulsteijn et al. 2012, Zheng et al. 2012, Ellis et al. 2013).

VPGLs can be resected via a transcervical approach. The risk for major vascular injury is smaller than in patients with carotid body PGLs. However, surgical resection of VPGLs almost always leads to the sacrifice of the vagus nerve, and sometimes palsy of other adjacent cranial nerves (Suarez et al. 2013). Surgery of VPGLs should be performed in rapidly enlarging tumors and large tumors that are compressing vital structures (such as the trachea). In other cases, therapeutic radiation (radiotherapy, radiosurgery) is recommended as a first-line therapeutic approach. Observation may be considered in asymptomatic cases with a low risk of malignancy. An individual treatment is absolutely necessary in patients with HNPGLs. In patients with multiple HNPGLs, combination of different approaches may be required with a step-by-step approach. Before any treatment is started, these patients have to be extensively discussed at an interdisciplinary tumor board that is familiar with HNPGLs, and all the treatment options have to be discussed with the patient as well (Taieb et al. 2014).

**Vagal parathyroid tumors**

**Tumor origin and molecular genetics**

Vagal parathyroid adenomas can be found within the vagus nerve (intravagal) in the neck or most often in close contact with the vagus nerve along its course within the carotid sheath or in the mediastinum.

In an autopsy study, microscopic collections of parathyroid chief cells were detected in about 6% of
vagus nerves (Lack et al. 1988). The origin of vagal parathyroid tissue is still controversial. In humans, the parathyroid glands develop from the third and fourth pharyngeal pouches. The third pouches differentiate into the thymus and inferior parathyroid glands (or parathyroid III), whereas the fourth pouches yield the superior parathyroid glands (or parathyroid IV) and the ultimobranchial body. The third pouches are between arches 3 and 4, and the fourth pouches are between arches 4 and 6. Pharyngeal glands are thought to follow blood vessel networks to reach their final positions. Since arches 4 and 6 are innervated by the vagus nerve, it is therefore possible that a close association might occur between parathyroid tissue and the vagus nerve during morphogenetic movements. This association has led to the introduction of the concept of paravagal complex (Henry & Iacobone 2012).

Although substantial advances have been made, the mechanisms underlying parathyroid cell tumorigenesis are largely unknown. Germline mutations in MEN1, Ret proto-oncogene (RET), cell division cycle 73 (CDC73), previously known as HRPT2, and calcium-sensing receptor (CASR) cause inherited primary hyperparathyroidism (PHPT), which accounts for 5–10% of all cases. These mutations are commonly found in young patients with clinically nonfamilial PHPT (Starker et al. 2012). Other parathyroid tumors may be due to activation of the WNT/β-catenin signaling pathway (Westin 2016). Inactivating mutations of the CDC73 tumor suppressor gene have been reported in hyperparathyroidism–jaw tumor (HPT-JT) syndrome-related adenomas and parathyroid carcinomas, in association with the loss of nuclear expression of the encoded protein, parafibromin.

The most frequent case of PHPT is a single parathyroid adenoma located in a eutopic position, followed by multiglandular disease (sporadic or hereditary) in

---

**Table 2** Differential diagnosis of poststyloid retropharyngeal masses: imaging features on MRI and molecular imaging.

<table>
<thead>
<tr>
<th>Paraganglioma</th>
<th>Nodal metastasis</th>
<th>Schwannoma</th>
<th>Neurofibroma</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MRI</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Numerous arterial feeders: Spin echo: Flow voids (‘salt and pepper’ appearance on T1- and T2-weighted images) TOF: hyperintense vessels (corresponding to flow voids) 3D (or 4D) gadolinium angiograms: avid enhancement</td>
<td>Variable appearance Well-defined margins Moderate signal in T2 Restricted diffusion heterogeneous enhancement usual</td>
<td>Well defined margins Moderate-to-high signal intensity on T2 No restriction of diffusion Heterogeneous enhancement seen in large tumors with degenerative changes (cystic, pseudocystic)</td>
<td>Intradural extramedullary Schwannoma Central low signal on T2 may be seen (‘target sign’)</td>
</tr>
<tr>
<td><strong>PET/CT – ^18^F-FDG</strong></td>
<td>Moderate to high uptake (highly elevated in SDHx mutation carriers)</td>
<td>Low-to-high uptake depending on the primary tumor</td>
<td>Low-to-high uptake (even in benign cases)</td>
</tr>
<tr>
<td><strong>PET/CT – ^18^F-FDOPA</strong></td>
<td>High uptake</td>
<td>No significant uptake</td>
<td>No significant uptake</td>
</tr>
<tr>
<td><strong>PET/CT – ^68^Ga-SSA</strong></td>
<td>High uptake</td>
<td>No significant uptake</td>
<td>Low-to-high uptake (even in benign cases)</td>
</tr>
</tbody>
</table>

---

**Figure 4**
Sporadic VPGL. ^68^Ga-DOTATATE (A and B), curved planar reconstructions of a 3D-GRE T1 Vibe with gadolinium and fat suppression (C) and 3D-SE (space) T2wi (D). An avid ^68^Ga-DOTATATE VPGL (*) is located at the level of mandibular angle. Adjacent to the VGPL 3D MRI demonstrates in this case the vagus nerve involvement due to its abnormal thickening. Abnormal thickening of the nerve is seen from lesion to the skull base (pars vascularis of jugular foramen) and may be due to vasa nervorum arterial feeders and edema more than perineural spread. A full colour version of this figure is available at http://dx.doi.org/10.1530/ERC-16-0241.
15–20% of cases, and ectopic glands found in 5–7% of cases. Ectopic positions can be a consequence of abnormal migration during embryogenesis (congenital) or secondary to acquired migration by gravity (due to gland weight). At La Timone University hospital based on a previous 2720 parathyroidectomies for PHPT, ectopic parathyroid glands were observed in 94 cases. The causes of ectopia were attributed to incomplete (5%) or excessive (34%) migration of the parathyroid complex (PIII-derived), incomplete migration of PIV (7%), acquired ectopia (13%), subcapsular/intrathyroid (PIII–PIV) (27%), and the remaining cases were associated with the vagus nerve (14%) (Henry et al. 2000). The lowest vagal parathyroid adenomas corresponded to sites where the inferior laryngeal nerves recur (i.e. around subclavian artery on right and aortic arch on left). Parathyroid hyperplastic glands associated with the vagus nerve can also be observed in the setting of MEN1 and renal hyperparathyroidism.

**Diagnosis and imaging**

PHPT is the third most common endocrine disorder after diabetes and hyperthyroidism (al Zahrani & Levine 1997). Diagnosis relies on elevated ionized or total serum calcium with inappropriate normal or elevated serum PTH levels, and normal or elevated urinary calcium. Imaging is necessary when selecting candidates for a focused surgical approach. Neck ultrasound (US) imaging and parathyroid scintigraphy are commonly used. On neck US, parathyroid...
tumors usually appear as homogeneous hypoechoic well-demarcated masses, which contrasts the hyperechoic appearance of thyroid tissue. In contrast to normal cervical nodes, no hyperechoic hilum is seen. Calcification within the lesion is more common in parathyroid carcinoma or large parathyroid glands. Multiple small cysts can be seen. The use of color and power Doppler sonography usually shows marked intraparenchymal vascularity and in some cases, can identify the vascular pedicle. At the level of the thyroid gland (infrahyoid neck), US with a modern high-frequency probe (5–14 MHz) can identify the vagus nerve (Ha et al. 2011). Neck US can describe up to 20% of anterior anatomical variations of the vagus nerve course at the level of the infrahyoid neck.

On parathyroid scintigraphy, vagal parathyroid adenomas often appear as sestamibi-avid lesions, with lateral cervical elongated nodules. There is a clear advantage of parathyroid scintigraphy with single-photon emission computed tomography (SPECT)/CT over neck US in the localization of mediastinal parathyroid adenoma. MRI and 4D-CT are usually performed in the presence of a mediastinal ectopic gland on scintigraphy or as the primary imaging modalities in some centers. 4D-CT consists in a multiphasic acquisition (nonenhanced, arterial and delayed phases) with a multidetector CT scan (Hoang et al. 2014). In contrast with normal lymph nodes or thyroid gland, parathyroid adenoma demonstrates avid contrast agent uptake in arterial phase and washout in delayed phase. For ectopic parathyroid adenoma localization, accuracy of 4D-CT is high (>85%) (Hunter et al. 2012). In the past, preoperative imaging has failed to detect ectopic parathyroid tumors, especially in old case series, which led to unsuccessful cervical exploration (Arnault et al. 2010). Today, this is an extremely rare situation, especially with the use of $^{123}$I/semastibi planar pinhole and SPECT/CT acquisition (Hindie et al. 2015).

Due to the very low frequency of ectopia not accessible via a cervical incision (<2%), 4D-CT (or MRI) are usually performed after surgical failure (Henry 2010). In case of a cervical image of uncertain origin, an image-guided fine-needle aspiration for PTH assay may be performed (Bergenfelz et al. 2009). Interesting results have been reported with $^{11}$C-methionine and $^{11}$C-choline PET in patients with persistent/recurrent hyperparathyroidism (Hessman et al. 2008, Schalin-Jantti et al. 2013). However, $^{11}$C-based PET imaging is difficult to implement in routine clinical practice due to low availability and very short half-life. Excellent results with $^{18}$F-fluorocholine have also been reported (Lezaic et al. 2014, Orevi et al. 2014, Michaud et al. 2015) and this imaging modality may become an alternative to parathyroid scintigraphy at initial diagnosis. The use of selective venous sampling with assessment of PTH can be used in selected cases before reoperative surgery when other investigations are negative, equivocal, or discordant. A two-fold gradient of PTH level is required for confirmation of a parathyroid tumor and regionalization.

**Treatment**

Surgery is the only curative treatment for PHPT. Conventional surgery for PHPT relies on the inspection of the four parathyroid gland sites or identification of at least four parathyroid glands through bilateral cervical exploration (Russell & Edis 1982). Today, bilateral neck exploration is not necessary for all patients if preoperative imaging studies show single-gland disease with the use of intraoperative PTH assay to confirm biochemical cure. A focused parathyroidectomy can be performed (e.g. mini-open surgery, endoscopy) when preoperative imaging is consistent with a single-gland abnormality. If available, the assessment of serum intraoperative PTH monitoring can confirm complete removal of hypersecreting tissue. Ectopic glands can be a source of surgical failure. Positive localization of an ectopic gland is highly accurate and can facilitate a more focused surgical approach (Roy et al. 2013).

Enucleation of a genuine intravagal adenoma can be performed without sacrificing the vagus nerve. Identification of an aortopulmonary adenoma by imaging...
can avoid useless cervical incisions with the potential risk of extensive dissections and morbidity.

In absence of preoperative parathyroid imaging or in situations with negative results, the surgeon will suspect an ectopic gland when a parathyroid gland is missing from its normal location or in the presence of four normal glands. The latter situation is observed in presence of a vagal parathyroid adenoma since they are almost always derived from a supernumerary gland. The surgeon will first search for an ectopic PIII or IV gland depending on the missing gland. In presence of four normal glands, a supernumerary gland must be suspected. Most often, the adenoma is located in close contact with the thymus due to a fragmentation of PIII during the migration of the thyrothymic complex. The adenoma can be found in close contact with the vagus nerve or sometimes within the vagus nerve. Vagal parathyroid adenomas can be found in a high cervical intravagal position (Fig. 6) or in the mediastinum. In the mediastinum, they may be located in the superior mediastinum or in the middle mediastinum in the aortopulmonary window (Fig. 7).

In the latter location, the adenoma cannot be removed through cervicotomy and require a thoracic approach. In cases of unsuccessful cervical exploration and subsequent persistent disease, reoperation should be carefully decided, as the complication rate is higher than after initial surgery, even in experienced teams (Karakas et al. 2013). Accurate localization is essential to increase success rate and reduce the risk of complications (Hessman et al. 2008).

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References


Vagal endocrine tumors

Endocrine-Related Cancer


Received in final form 8 July 2016. Accepted 12 July 2016. Accepted Preprint published online 12 July 2016.